In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gliatech Inc.

Latest From Gliatech Inc.

Market Insight - Cost of capital in royalty monetisation transactions

In the current climate it is unsurprising that biopharmaceutical companies are tapping alternative sources of financing, including royalty monetisation for commercial products. Dr Ken Macleod, John Leone and Dr Walter Flamenbaum explain how investors weigh up risk when valuing such transactions.

Metabolic Disorders Gynecology & Urology

Genzyme Bets Big on Biosurgery

Genzyme Corp is merging two of its subsidiaries, Genzyme Tissue Repair and Genzyme Surgical with a third company, Biomatrix Inc. in a bold bet on the promise of biosurgery--the combination of biomaterials and gene and cellular therapies with more traditional surgical instruments. Clinically, biosurgery will hopefully improve patient outcomes; commercially, it will differentiate surgical instrument makers whose products seem increasingly alike.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials